News

Otsuka snags Lu AE58054
Enlarge image

BusinessDenmark

Otsuka snags Lu AE58054

28.03.2013 - Japanese Otsuka and Danish Lundbeck have inked a US$825m co-development and co-marketing deal in Alzheimer's disease.

Under the terms of the agreement, the Copenhagen-based neurology specialist will grant Otsuka (Tokyo) co-development and co-commercialisation rights to its selective 5-HT6-receptor antagonist LU AE58054 in the US, Canada, East Asia, Japan, and major European pharma markets.

The Japanese company will pay US$150m upfront. Both companies will share the sales, development, and commercialisation costs. Lundbeck is also entitled to up to US$675m in milestones.  

A pivotal clinical programme with Lu AE58054 enroling more than 2,500 patients with mild-to-moderate Alzheimer's disease is planned to be initiated later this year. Lu AE58054 will be tested as adjunct treatment to donepezil. Last May, Lundbeck reported that Lu AE58054 had met its primary endpoint in a 24-week clinical Phase II trial in 278 patients in the same setting as the confirmatory Phase III study.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/otsuka-snags-lundbecks-lu-ae58054.html

EU

04.09.2015 Crowdfinancing has just recently emerged as a financing instrument in the Life Sciences. A new report lists 42 European companies in the sector that have raised a total of almost €23m.

DiabetesFrance

01.09.2015 Sanofi is partnering up with Google’s life sciences team with an ambitious goal: to change the face of diabetes management.

M&ASwitzerlandFrance

31.08.2015 In order to boost its active cosmetic ingredients business, the Swiss flavour and fragrance giant Givaudan has acquired Volketswil-based Induchem Holding and all its subsidiaries.

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • EVOLVA (CH)1.49 CHF12.03%
  • TIGENIX (B)1.23 EUR9.82%
  • OREXO (S)49.10 SEK8.39%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)11.35 SEK-11.67%
  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • PROTHENA PLC (IE)52.70 USD-6.54%

TOP

  • KARO BIO (S)41.90 SEK2424.1%
  • BIOTECH PHARMACON (N)16.80 NOK76.8%
  • TIGENIX (B)1.23 EUR73.2%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • NEUROVIVE PHARMACEUTICAL AB (S)11.35 SEK-48.4%
  • THROMBOGENICS (B)2.85 EUR-43.0%

TOP

  • KARO BIO (S)41.90 SEK4661.4%
  • ADOCIA (F)89.30 EUR434.4%
  • GALAPAGOS (B)53.25 EUR330.1%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)11.35 SEK-82.2%
  • BIOTEST (D)20.30 EUR-76.5%

No liability assumed, Date: 04.09.2015